Impact of closure devices on vascular complication and mortality rates in TAVI procedures. (15th August 2017)

• Record Type: Journal Article
• Authors: Dimitriadis, Zisis; Scholtz, Werner; Börgermann, Jochen; Wiemer, Marcus; Piper, Cornelia; Vlachojannis, Mario; Gummert, Jan; Horstkotte, Dieter; Ensminger, Stephan; Faber, Lothar; Scholtz, Smita
• Is Part Of: International journal of cardiology. Volume 241(2017)
• Page Start: 133
• Page End: 137
• Publication Date: 2017-08-15
• Subjects: TAVI -- Vascular complications -- Closure devices -- Mortality -- VARC II criteria; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2017.01.088
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background: Currently two closure devices are available for the vascular access in TAVI procedures. Their impact on vascular complications and mid-term mortality is yet unknown. Methods: Between 2009 and 2014, 398 patients underwent TAVI TF procedures in which two different closure devices were used, Prostar® XL ( n = 215) and Perclose-Proglide® ( n = 183). In the cases with Prostar we used one device and in cases with Perclose-Proglide, two devices. The two groups were compared with respect to the criteria of the Valve Academic Research Consortium (VARC) II. The mean follow-up period was 679.7 ± 481.8 (727) days. Results: There were no significant differences in the baseline characteristics of both patient groups. In the Prostar® group, complications were more frequent (26.6% vs. 12.6%, p = 0.005); in detail, these were bleeding (14.9% vs. 7.1%, [ p ] = 0.02), suture rupture (4.7% vs. 1.3%, p = 0.04), and pseudoaneurysms (10.2% vs. 1.2%, p < 0.001). Multivariate regression analysis revealed two predictors for vascular complications: female sex (OR 2.3; 95% CI 1.3–3.8, p = 0.002) and closure devices (OR 0.5; 95% CI 0.3–0.8, p = 0.007) in favour of Proglide®. There was no significant difference in 30-day mortality (Prostar: 5.6 ± 1.6% vs. Proglide: 4.9 ± 1.6%). However, Kaplan-Meier survival analysis showed a significantly higher survival rate over the entire follow-up period for the Proglide® group ( p = 0.03). Conclusion: Vascular complications occurred more often in the Prostar® group. Although 30-day mortality showed no significant difference between the groups, the mortality over complete follow-up was significantly lower in the Proglide® group.